Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Upender Velaparthi

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of the American Chemical Society|September 9, 2025
Diversity-Oriented C-H Activation Reactions of the Naphthalene ScaffoldZhoulong Fan, Md Emdadul Hoque, Kevin Wu, et al.
Bioorganic & Medicinal Chemistry Letters|April 3, 2007
Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profileUpender Velaparthi, Peiying Liu, Balu Balasubramanian, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinaseMark D Wittman, Balu Balasubramanian, Karen Stoffan, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2008
2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924Mark G Saulnier, David B Frennesson, Mark D Wittman, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2008
Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitorsKurt Zimmermann, Mark D Wittman, Mark G Saulnier, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2010
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-oneUpender Velaparthi, Mark G Saulnier, Mark D Wittman, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2022
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancerChetan Padmakar Darne, Upender Velaparthi, Mark Saulnier, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2007
Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)Upender Velaparthi, Mark Wittman, Peiying Liu, et al.
Journal of Medicinal Chemistry|September 4, 2008
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activityUpender Velaparthi, Mark Wittman, Peiying Liu, et al.
Bioorganic & Medicinal Chemistry Letters|February 16, 2010
SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitorsKurt Zimmermann, Mark D Wittman, Mark G Saulnier, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of the American Chemical Society|September 9, 2025
Diversity-Oriented C-H Activation Reactions of the Naphthalene ScaffoldZhoulong Fan, Md Emdadul Hoque, Kevin Wu, et al.
Bioorganic & Medicinal Chemistry Letters|April 3, 2007
Imidazole moiety replacements in the 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profileUpender Velaparthi, Peiying Liu, Balu Balasubramanian, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinaseMark D Wittman, Balu Balasubramanian, Karen Stoffan, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2008
2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924Mark G Saulnier, David B Frennesson, Mark D Wittman, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2008
Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitorsKurt Zimmermann, Mark D Wittman, Mark G Saulnier, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2010
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-oneUpender Velaparthi, Mark G Saulnier, Mark D Wittman, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2022
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancerChetan Padmakar Darne, Upender Velaparthi, Mark Saulnier, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2007
Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)Upender Velaparthi, Mark Wittman, Peiying Liu, et al.
Journal of Medicinal Chemistry|September 4, 2008
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activityUpender Velaparthi, Mark Wittman, Peiying Liu, et al.
Bioorganic & Medicinal Chemistry Letters|February 16, 2010
SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitorsKurt Zimmermann, Mark D Wittman, Mark G Saulnier, et al.
Pageof 2